We sat down for a long form, in depth discussion with Paul Rennie from Paradigm Biopharmaceuticals.

 

PAR has been a core holding for FiftyOne Capital almost from inception and we foresee some major catalysts ahead for the company.

 

The information in this podcast is strictly general in nature and is not advice or based on your personal situation. Do your own research.